Compare Berkshire Hathaway Inc Class B (BRK.B) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs CVS Health Corp — how do they compare? Berkshire Hathaway Inc Class B trades at $516.89, while CVS Health Corp trades at $93.68 (market cap $122.36B). The key difference: CVS Health Corp pays a 2.78% dividend while Berkshire Hathaway Inc Class B pays none, and Berkshire Hathaway Inc Class B is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| BRK.B | CVS | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $529.65 | $110.60 |
52-Week Low | $465.39 | $65.51 |
Market Cap | — | $122.36B |
Enterprise Value | — | $184.71B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $529.65, up 1.73% today, with a bullish technical signal from moving averages and oscillators. Analyst consensus is positive with 57% buy ratings, though key valuation and profitability ratios are not provided in the input data. Recent business performance and cash flow details are unavailable for the current period.
The outlook is supported by bullish technicals and analyst sentiment, but investment decisions require verified fundamentals like earnings growth and valuation metrics. Risks include market volatility and reliance on broader economic conditions, with no recent news to drive near-term catalysts.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
